TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3396401

Group type: EXPERIMENTAL
Intervention: Oral placebo (single dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral placebo (1-2 weeks of therapy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral placebo (Group 1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral placebo (Group 2)
Number of subjects: 19
Study: 29457876

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg single dose
Number of subjects: 20
Study: 27297718

Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg/d)
Number of subjects: 117
Study: 25045865

Group type: EXPERIMENTAL
Intervention: Information about food consumption of overweight individuals
Number of subjects: 80

Group type: COMPARATOR
Intervention: Information about food consumption of normal/healthy weight individuals
Number of subjects: 80
Study: 22525385

Group type: EXPERIMENTAL
Intervention: Montelukast alone
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Montelukast plus add-on loratadine
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 21122699

Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: ERN 1 g
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1613
Study: 18295172

Group type: EXPERIMENTAL
Intervention: Human papillomavirus/Papanicolaou test smear group
Number of subjects: 674

Group type: COMPARATOR
Intervention: Papanicolaou test smear only group
Number of subjects: 674
Study: 15791966

Group type: EXPERIMENTAL
Intervention: Pomeroy ligation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Bipolar coagulation
Number of subjects: 109
Study: 11814493

Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole, 37.5 mg twice daily for 5 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo gel twice daily for 5 days
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 106
Study: 10748847

Group type: EXPERIMENTAL
Intervention: Nasal splints
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-splinted group
Number of subjects: 110
Study: 8748566

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 2000
Study: 1663860

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 6994789

Group type: EXPERIMENTAL
Intervention: Homoeopathic remedies
Number of subjects: 23

Group type: COMPARATOR
Intervention: Inert preparation (placebo)
Number of subjects: 23
Study: 31552981

Group type: EXPERIMENTAL
Intervention: 500 mg free EA
Number of subjects: 0

Group type: COMPARATOR
Intervention: 237 mL PomJ (∼120 mg of EA)
Number of subjects: 0
Study: 27913970

Group type: EXPERIMENTAL
Intervention: Active group (LLLT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 34
Study: 26475500

Group type: EXPERIMENTAL
Intervention: Multimedia-based intervention consisting of 12 brief contact interventions (BCIs) delivered over six months.
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 630
Study: 22712831

Group type: EXPERIMENTAL
Intervention: Influenza virus positive individuals
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Other respiratory viruses
Number of subjects: 586

Group type: COMPARATOR
Intervention: Virus negative population (reference)
Number of subjects: 586
Study: 21323872

Group type: EXPERIMENTAL
Intervention: Senicapoc
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 19328861

Group type: EXPERIMENTAL
Intervention: Pirfenidone with food
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pirfenidone without food
Number of subjects: 16
Study: 17238034

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 0
Study: 15895314

Group type: EXPERIMENTAL
Intervention: exercise/calcium
Number of subjects: 113

Group type: COMPARATOR
Intervention: exercise/placebo
Number of subjects: 113

Group type: COMPARATOR
Intervention: sedentary/calcium
Number of subjects: 113

Group type: COMPARATOR
Intervention: sedentary/placebo
Number of subjects: 113
Study: 17943665

Group type: EXPERIMENTAL
Intervention: GAME(Wheels) system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Without GAME(Wheels) system (control)
Number of subjects: 10
Study: 9815298

Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously, three times a week (Arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously every day (Arm B)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously every day + sargramostim, 250 micrograms subcutaneously on non-5-FU days (Arm C)
Number of subjects: 81

Group type: COMPARATOR
Intervention: All arms received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IFN beta ser on intermittent schedule (Arm A)
Number of subjects: 81
Study: 7708002

Group type: EXPERIMENTAL
Intervention: octreotide (daily doses between 100 and 1000 micrograms)
Number of subjects: 7
Study: 2706913

Group type: EXPERIMENTAL
Intervention: Vibration (20 Hz, 20 m/s2 RMS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 14
Study: 341935

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline (1:200 000)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etidocaine 1.5% with adrenaline (1:200 000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etidocaine 1% without adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etidocaine 1.5% without adrenaline
Number of subjects: 40
Study: 31315910

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 14174

Group type: EXPERIMENTAL
Intervention: Hip Circumference
Number of subjects: 14174

Group type: EXPERIMENTAL
Intervention: ADpSGEGDFXAEGGGVR* (fibrinogen-cleavage peptide)
Number of subjects: 14174

Group type: EXPERIMENTAL
Intervention: O-sulfo-l-tyrosine
Number of subjects: 14174

Group type: EXPERIMENTAL
Intervention: Lung Adenocarcinoma
Number of subjects: 14174
Study: 29454009

Group type: EXPERIMENTAL
Intervention: Hypothermia for 24 hours (33 ± 1 °C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hypothermia for 72 hours (33 ± 1 °C)
Number of subjects: 34
Study: 26305143

Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine ER
Number of subjects: 95

Group type: COMPARATOR
Intervention: 4 mg tolterodine ER
Number of subjects: 95
Study: 24865872

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 330
Study: 22112544

Group type: EXPERIMENTAL
Intervention: Inadequate FSG at baseline (defined as depth of insertion <50 cm or visual inspection limited to <90% of mucosal surface without detection of a polyp or mass)
Number of subjects: 64554

Group type: EXPERIMENTAL
Intervention: Inadequate FSG due to depth of insertion <50 cm
Number of subjects: 64554

Group type: EXPERIMENTAL
Intervention: Inadequate FSG despite adequate depth of insertion
Number of subjects: 64554

Group type: EXPERIMENTAL
Intervention: Age and sex factors associated with inadequate FSG
Number of subjects: 64554

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m(2))
Number of subjects: 64554

Group type: EXPERIMENTAL
Intervention: Inadequate FSG at baseline
Number of subjects: 64554
Study: 18440668

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate tissue adhesive
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 186
Study: 17585002

Group type: EXPERIMENTAL
Intervention: Cataract surgery (expedited, approximately four weeks)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control (routine, 12 months wait)
Number of subjects: 306
Study: 15035964

Group type: EXPERIMENTAL
Intervention: Grimaldi's method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 11511433

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 9747999

Group type: EXPERIMENTAL
Intervention: Temporary prostheses provided to doubtful ambulators, double amputees, blind persons, and those with psychiatric disorders.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prosthetic limb provision policy.
Number of subjects: 60
Study: 7851032

Group type: EXPERIMENTAL
Intervention: Lisinopril (mean dose: 6.4 +/- 4 mg) for 6 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 19
Study: 3385411

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 90

Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mood induction (Velten's procedure)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bogus feedback
Number of subjects: 90
Study: 29111784

Group type: COMPARATOR
Intervention: Bright Light Therapy (BLT) only
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of Bright Light Therapy (BLT) and Wake Therapy (WT)
Number of subjects: 62
Study: 28195995

Group type: EXPERIMENTAL
Intervention: TX-004HR (4-, 10-, and 25-μg)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: TX-004HR
Number of subjects: 764
Study: 25140047

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23450660

Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg/day
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 22017799

Group type: COMPARATOR
Intervention: Passive warming with blankets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Passive warming with blankets + active warming using a chemical heat pad
Number of subjects: 48
Study: 18440821

Group type: EXPERIMENTAL
Intervention: Everolimus (0.75-10mg) daily for 21 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17137905

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12648202

Group type: EXPERIMENTAL
Intervention: 3 mg of hyperbaric bupivacaine + 10 microg fentanyl (B3F)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4 mg of hyperbaric bupivacaine (B4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 16198237

Group type: EXPERIMENTAL
Intervention: Edaravone (administered to 27 patients: GIa, n = 13; GIIa, n = 14)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (GIb, n = 11; GIIb, n = 13)
Number of subjects: 51
Study: 10512125

Group type: EXPERIMENTAL
Intervention: Miso soup intake
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Pickles intake (excluding salted fish)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Soybeans intake
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Tofu consumption
Number of subjects: 999
Study: 7491379

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 2321570

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (65 mg/d for 2 weeks, 5 mg/d for 4 weeks, 605 mg/d for 3 weeks, 5 mg/d for 4 weeks, average 375 mg/d for 1 week)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ascorbic acid deficiency
Number of subjects: 11
Study: 6270996

Group type: EXPERIMENTAL
Intervention: Various test diets (specific dietary components)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study: 31062207

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 25
Study: 31280826

Group type: EXPERIMENTAL
Intervention: Fast-track protocol in the emergency department (ED)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Thrombolysis in ED
Number of subjects: 126

Group type: COMPARATOR
Intervention: Prehospital delay
Number of subjects: 126
Study: 28296581

Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg orally twice per day
Number of subjects: 46
Study: 26255281

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (800 mg BA + 8 g dextrose, 4 doses/day for 28 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PLA; 8 g dextrose, 4 doses/day for 28 days)
Number of subjects: 22
Study: 23826907

Group type: EXPERIMENTAL
Intervention: Pfannenstiel laparoendoscopic single-site donor nephrectomy (LESS-DN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional laparoscopic donor nephrectomy (LDN)
Number of subjects: 29
Study: 20947819

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metformin (2 g/d)
Number of subjects: 37
Study: 19042115

Group type: EXPERIMENTAL
Intervention: SFC 50/250microg
Number of subjects: 282

Group type: COMPARATOR
Intervention: FP 250microg
Number of subjects: 282

Group type: COMPARATOR
Intervention: SAL 50microg
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: General treatment
Number of subjects: 282
Study: 16973786

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) over 6 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Monthly monitoring
Number of subjects: 58
Study: 13680307

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (non-obese patients)
Number of subjects: 160
Study: 11529246

Group type: EXPERIMENTAL
Intervention: rAAV-GAD gene transfer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (physiological saline)
Number of subjects: 20
Study: 9631952

Group type: EXPERIMENTAL
Intervention: Pergolide (0.05 mg BID) for 8 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 12
Study: 7836186

Group type: EXPERIMENTAL
Intervention: Strength training program (16 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 30340618

Group type: EXPERIMENTAL
Intervention: Geriatrician-led admission avoidance hospital at home
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inpatient admission
Number of subjects: 36
Study: 28533093

Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine (two intranasal doses of 0.25 mL per nostril, 21 days apart)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine (two doses)
Number of subjects: 152

Group type: COMPARATOR
Intervention: H5N1 booster vaccine (one intramuscular dose of 0.5 mL)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine
Number of subjects: 152
Study: 26556097

Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 23314060

Group type: EXPERIMENTAL
Intervention: Plasma protein panel (5 proteins identified)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Training sample of plasma analytes (107 analytes)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Biological pathway analysis
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E
Number of subjects: 167
Study: 21187295

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 114
Study: 18361342

Group type: EXPERIMENTAL
Intervention: Philips Sonicare FlexCare
Number of subjects: 93

Group type: COMPARATOR
Intervention: Oral-B Triumph
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Difference between FlexCare and Triumph
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combined overall treatment effect from two studies
Number of subjects: 93
Study: 17161267

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation (CPVA)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 198
Study: 12708602

Group type: EXPERIMENTAL
Intervention: SB-LOT (90 mg coumarin + 540 mg troxerutin/d)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: CYP2A6 polymorphism
Number of subjects: 231
Study: 10997840

Group type: EXPERIMENTAL
Intervention: Formal videotrainer skills training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 8715321

Group type: EXPERIMENTAL
Intervention: Technique of drop administration taught to patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home caregiver applying drops
Number of subjects: 0
Study: 1396198

Group type: EXPERIMENTAL
Intervention: Nimorazole 2G (Naxogin Farmitalia Carlo Erba, Italy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nimorazole 4G in two equally divided doses 24 hours apart (2GBD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nimorazole 3G
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tinidazole 2G (Fasigyn, Pfizer Ltd)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ornidazole 1.5G (Tiberal, Roche, Switzerland)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nimorazole 2GBD
Number of subjects: 72
Study: 2868495

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29843659

Group type: EXPERIMENTAL
Intervention: Crossroads‐II study intervention involving a face to face household survey and additional questionnaires and biophysical measurements.
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Crossroads‐II study intervention with a composite measure of health service access.
Number of subjects: 3600
Study: 27118042

Group type: EXPERIMENTAL
Intervention: Web-based education with poster reminder intervention
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control group (posttest only)
Number of subjects: 564
Study: 24831919

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (BG: 70‐110 mg/dL)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard glycemic control (BG: 70‐180 mg/dL)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 93
Study: 22277266

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil)
Number of subjects: 40
Study: 19644691

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) program and exercises
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment and exercises
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (only exercises)
Number of subjects: 59
Study: 18483859

Group type: EXPERIMENTAL
Intervention: Televised training with limited technical assistance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Televised training alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 16008114

Group type: EXPERIMENTAL
Intervention: Korodin (25 drops, applied once, followed by daily 3 x 25 drops for 7 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (single application and daily treatment for 7 days)
Number of subjects: 39
Study: 12145174

Group type: EXPERIMENTAL
Intervention: Intensive diet and exercise group
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Ala12 allele
Number of subjects: 522
Study: 10368079

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ) 1,200 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7729443

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training (24 sessions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High HRV group (n = 5)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low HRV group (n = 5)
Number of subjects: 34
Study: 1970226

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7315901

Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 29023649

Group type: EXPERIMENTAL
Intervention: Perceptual individuation training
Number of subjects: 95
Study: 29114894

Group type: EXPERIMENTAL
Intervention: INCS plus montelukast for 1 year
Number of subjects: 72

Group type: COMPARATOR
Intervention: INCS in monotherapy
Number of subjects: 72
Study: 26575323

Group type: EXPERIMENTAL
Intervention: 50 μg salmeterol treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 μg salmeterol treatment
Number of subjects: 10
Study: 23860881

Group type: EXPERIMENTAL
Intervention: IgM autoantibodies against phosphorylcholine (anti-PC)
Number of subjects: 3356
Study: 22581070

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Functional adaptation skills training
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combined treatment (cognitive remediation + functional skills training)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Cognitive remediation alone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Functional skills training
Number of subjects: 107
Study: 20875883

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 18590350

Group type: EXPERIMENTAL
Intervention: XP-828L (800 mg daily for 56 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26
Study: 15708732

Group type: EXPERIMENTAL
Intervention: Heterogeneous VaD group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcortical infarct or SH-only subtype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphometric changes (increased subcortical hyperintensities, decreased whole brain volume)
Number of subjects: 0
Study: 14628497

Group type: EXPERIMENTAL
Intervention: Androgen supplementation therapy (testosterone replacement therapy)
Number of subjects: 0